Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative products for the diabetes, cancer, dermatology, and drug delivery markets. Founded in 1998 and headquartered in San Diego, California, Halozyme leverages its proprietary recombinant human hyaluronidase platform technology to enhance drug delivery and efficacy. The company collaborates with pharmaceutical partners to apply its technology across various therapeutic areas, aiming to improve patient outcomes and ease the burden of treatment.
Halozyme has made significant strides in the biotech industry, becoming a publicly traded company on Nasdaq under the ticker HALO and a component of the S&P 400. Its disruptive drug delivery technologies have garnered attention for their potential to transform patient care. The company's commitment to innovation and patient-centric solutions has solidified its reputation as a leader in the biopharmaceutical sector.
